AzTrials
AzTrials

Cardiovascular DiseasePAUSENCT03520400

PCI Alternative Using Sustained Exercise

A study testing Exercise Therapy in people with Cardiovascular Disease, run by VA Office of Research and Development at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Cardiovascular disease remains the leading cause of morbidity and mortality in the U.S. and is a major cause of disability in Veterans. Most of these deaths are due to coronary artery disease (CAD). Read more about this study

Who is it for?
Ages 45 to 75 years
Conditions the study is for
Cardiovascular Disease
What is being tested?
Exercise Therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
51 participants
Where
1 siteUnited States
Study dates
1 Oct 2012to 30 Sep 2019
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Stable patients who have lesions appropriate for PCI based on American Heart Association/American College of Cardiology criteria will be considered for the study.
  • Only patients with a good prognosis (annual mortality <2% based on VA multivariate scores (57, 58) will be considered.

Who cannot join

  • Patients with left main disease or proximal LAD disease, or:
  • Unstable angina
  • A history of left ventricular dysfunction (EF 30%)
  • Pacemakers
  • Atrial fibrillation
  • Myocardial infarction within the last 3 months
  • Diabetes
  • Orthopedic problems interfering with the ability to exercise regularly

Trial locations and contacts

1 site in 1 country.

United States1 site
  • VA Palo Alto Health Care System, Palo Alto, CA

    Palo Alto, California, 94304-1290

Other trials in United States

About this study

Official title: PCI Alternative Using Sustained Exercise (PAUSE)

Cardiovascular disease remains the leading cause of morbidity and mortality in the U.S. and is a major cause of disability in Veterans. Most of these deaths are due to coronary artery disease (CAD). The most common treatment for CAD is revascularization, an invasive procedure which usually involves placing a stent inside an artery that is diseased. However, exercise training is often overlooked because clinicians tend to focus on repairing the coronary circulation and the potential need for revascularization. Studies have shown that exercise training can be effective for patients with CAD and that it saves costs. In this study, invasive revascularization will be compared to a structured program of exercise training over one year. Comparisons will be made between groups for symptoms, coronary artery size and function using PET/CTA, and health care cost utilization.

Read the detailed description

Despite advances in treatment options for cardiovascular disease (CVD), this condition remains the leading cause of morbidity and mortality in the U.S. and is a major cause of disability in Veterans. Percutaneous coronary intervention (PCI) is the treatment most often used in patients with various manifestations of coronary artery disease (CAD). While it is commonly assumed that PCI also reduces mortality, randomized trials have shown that PCI has no effect on mortality except in patients being treated for acute myocardial infarction. Over the last decade, the use of PCI has increased exponentially; between 1996 and 2007, the number of PCIs performed in the US has increased more than 4-fold, from approximately 300,000 to more than 1.3 million yearly. During this time, PCI has accounted for 10% of the overall increase in Medicare expenditures. In light of the extraordinary increase in the use of this technology in recent years, questions have been raised regarding the cost-effectiveness of PCI, the extent to which PCI is overused, and whether selected patients may benefit from optimal medical therapy in lieu of PCI. Cost analyses have suggested that the current rate of increase in PCI with DES is unsustainable for the U.S. healthcare system. Given the costs associated with PCI, there have been recent efforts to compare outcomes and effectiveness of PCI against non-invasive therapy.

There is a need to evaluate more judicious use of PCI, and to consider less costly interventions for at least some of the >1.3 million patients in the U.S. who undergo this procedure. Lifestyle intervention, including exercise training, is one option that has been shown to result in reduced symptoms, better exercise tolerance, improved quality of life and lower mortality. A growing body of data has demonstrated that exercise intervention improves coronary anatomy and lessens ischemia through enhanced endothelial function. While a significant proportion of health care expenditures are devoted to PCI and other invasive interventions for CVD, few health care resources are directed toward primary or secondary prevention. Recent studies have demonstrated that programs of cardiac rehabilitation, with and without implementation of intensive risk reduction, are cost effective. In part because of the financial interests associated with PCI, exercise and lifestyle intervention is rarely considered as a clinical treatment option in PCI candidates. A gap exists between the standard clinical treatment for CAD and the potential for non-invasive, less expensive and potentially more effective treatments for these patients. Previous efforts to quantify the effects of exercise and lifestyle intervention on coronary artery perfusion and anatomy have been limited to standard angiography. In recent years, improved technologies for imaging coronary perfusion and anatomy have been developed, which could provide important insights into the effects of exercise training on the heart. These include the combination of positron emission tomography and ultra-fast computed tomography angiography (CTA), commonly termed PET/CTA. PET provides information on the functional significance of anatomic stenoses by measuring myocardial blood flow and myocardial perfusion reserve. PET can also be used to evaluate coronary endothelial function by measurements of changes in myocardial blood flow in response to physical stimuli (i.e., cold pressor testing). The combination of CTA with PET also allows for improved attenuation correction. CTA, on the other hand, can noninvasively image the coronary arteries to determine the severity of stenosis and the amount of calcified and noncalcified plaque burden.

The investigators have termed the current proposal "PCI Alternative Using Sustained Exercise" (PAUSE) to reflect the potential for exercise training and lifestyle intervention as alternative therapies in selected PCI candidates.

Primary aim: To determine whether subjects with lesions amenable to PCI randomized to a 1 year exercise program and lifestyle intervention have greater improvement in coronary perfusion and function than those randomized to PCI.

Secondary analyses: The investigators will compare exercise test responses, health care costs, quality of life, and clinical outcomes between groups.

Being tested
Exercise Therapy
Keywords
Cardiovascular Disease, Percutaneous Intervention, coronary artery disease, exercise therapy
Medical subject headings
Cardiovascular Diseases, Coronary Artery Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Exercise TherapyBehavioural

    Also called Exercise Training

    Patients will adhere to one year of exercise therapy for the investigators' study. At minimum, subjects will aim to participate in approximately 30-60 minutes of aerobic exercise 5-7 days per week and 15-30 minutes of resistance/anaerobic exercise 2-3 times per week.

Study groups in NCT03520400
Study groupRoleWhat they receive
Exercise Intervention GroupExperimentalGroup receives one year of exercise and lifestyle intervention
Receives: Behavioral: Exercise Therapy
PCI group (usual care)No interventionGroup receives standard clinical care with no intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Myocardial Perfusion Reserve

    Measurement of myocardial blood flow has only been analyzed at baseline at this time. Intravenous 13NH3 will be used as the flow tracer and serial imaging with PET will be performed. Measurements will be performed at baseline, and after pharmacologic stress with dipyridamole. Myocardial blood flow at rest and following dipyridamole infusion will be expressed as ml flow/100 g/min. The myocardial perfusion reserve will be calculated as the ratio of the myocardial blood flow during stress (e.g. after dipyridamole) and the myocardial blood flow at rest. Commercially available software (Emory tool box) will be used to quantitatively analyze PET myocardial perfusion images.

    Measured: baseline and 1 year

Secondary outcomes (1)
  1. Peak VO2

    Peak VO2 will be determined at baseline and 1 year on a treadmill using an individualized ramp protocol with collection of continuous ventilatory gas exchange responses.

    Measured: baseline and after 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 May 2018
  2. Study start1 Oct 2012
  3. Primary completion30 Sep 2019
  4. Study completion30 Sep 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized controlled trial
Masking
None (open label)
Enrolment
51 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03520400
Sponsor's protocol ID
F7374-R
Acronym
PAUSE
Status last verified
May 2023
First submitted
27 Apr 2018
Last updated
2 Feb 2024
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Upon completion of the study, de-identified data will be made available to collaborative institutions with whom the investigators are in contact.

Questions about this trial

What is this clinical trial studying?

A study testing Exercise Therapy in people with Cardiovascular Disease, run by VA Office of Research and Development at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 20 Sep 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Myocardial Perfusion Reserve (time frame: baseline and 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in